Reporting
Understanding COVID-19 vaccine confidence in people living with HIV in Canada: A pan-Canadian survey
Learn MoreEnrolling
Virtual PrEP: Rendering PrEP delivery more efficient using an mHealth intervention and TAF/FTC
Learn MoreOngoing
Optimising Outcomes at Critical Points in the Cascade of HIV Care in Ontario
Learn MoreEnrolling
Electronic capture through the Opal patient portal of a patient-reported measure of barriers to antiretroviral therapy adherence: a mixed method type 3 hybrid pilot study at a large Montreal HIV clinic
Learn MoreCompleted
Transgender women removing healthcare barriers to engagement in the HIV prevention and care cascades
Learn MoreReporting
Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (ECF/TAF) Switch followed by Sofosbuvir/Velpatasvir (SOF/VEL) Antiviral HCV Therapy in HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy — A Pilot Feasibility Study
Learn MoreStart-up
Decentralizing the delivery of HIV pre-exposure prophylaxis (PrEP) through family physicians and sexual health clinic nurses
Learn MoreOngoing
HIV Prevention for Gay, Bisexual, and other Men Who Have Sex with Men
Learn MoreOngoing
Evaluation of web-based interventions to support people living with HIV in the adoption of health behaviours
Learn More
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.
